Medical Physics Seminar - Stephen A. Graves, Ph.D., DABR
Developments in Radiopharmaceutical Therapy and the Need for Foundational Infrastructure in Support of Patient-Tailored Treatments
Event Details
Date
Monday, November 21, 2022
Time
4-5 p.m.
Location
Description
The use of radiopharmaceutical therapy has rapidly expanded with the recent approvals of 177Lu-DOTATATE for neuroendocrine tumors and 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer. More than 300 ongoing clinical trials are exploring new agents, new treatment indications, and combination therapy approaches. It is likely that this modality will grow to account for a significant fraction of patients receiving radiation therapy. As such, foundational infrastructure is urgently n
Cost
Free